Lista de obras - Ivan Spicka - Dominio Público Uruguay

A dose exploration, phase I/II study of administration of continuous erythropoietin receptor activator once every 3 weeks in anemic patients with multiple myeloma receiving chemotherapy

scientific article published on 01 April 2007

A first Czech analysis of 1887 cases with monoclonal gammopathy of undetermined significance

artículo científico publicado en 2017

A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma.

artículo científico publicado en 2015

Adjusted comparison of daratumumab monotherapy versus real-world historical control data from the Czech Republic in heavily pretreated and highly refractory multiple myeloma patients.

artículo científico publicado en 2017

Advances in multiple myeloma therapy during two past decades

artículo científico

An overview of the VISTA trial: newly diagnosed, untreated patients with multiple myeloma ineligible for stem cell transplantation

Asymptomatic and Treatment-requiring Multiple Myeloma - Data from the Czech Registry of Monoclonal Gammopathies

artículo científico publicado en 2017

Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial

artículo científico publicado en 2010

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

artículo científico publicado en 2008

Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up.

artículo científico publicado en 2015

Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.

artículo científico publicado en 2016

Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study

artículo científico publicado en 2017

Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment

artículo científico publicado en 2017

Change in ploidy status from hyperdiploid to near-tetraploid in multiple myeloma associated with bortezomib/lenalidomide resistance

artículo científico publicado en 2014

Characterization of a new human plasma cell leukemia cell line UHKT-944.

artículo científico publicado en 2015

Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial

artículo científico publicado en 2011

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

article

Continuous prednisolone versus conventional prednisolone with VMCP-interferon-alpha2b as first-line chemotherapy in elderly patients with multiple myeloma.

artículo científico publicado en 2005

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

artículo científico publicado en 2016

Distinguishing of primary mediastinal B-cell lymphoma and diffuse large B-cell lymphoma using real-time quantitative polymerase chain reaction

artículo científico publicado en 2010

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

artículo científico publicado en 2015

Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth

artículo científico publicado en 2017

Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma

article

Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma.

artículo científico publicado en 2016

Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy.

artículo científico publicado en 2010

Health-Related Quality of Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.

artículo científico publicado en 2016

Histone deacetylase inhibitors in plasma cell leukemia treatment: effect of bone marrow microenvironment.

artículo científico publicado en 2017

IgM myeloma: A multicenter retrospective study of 134 patients

artículo científico publicado en 2017

Immunotactoid glomerulonephritis as a cause of acute renal failure

scientific article published on 01 April 2004

Multicentered patient-based evidence of the role of free light chain ratio normalization in multiple myeloma disease relapse.

artículo científico

Novel human multiple myeloma cell line UHKT-893 ⬇️

artículo científico publicado el 3 de enero de 2013

Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production

artículo científico publicado en 2003

Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.

artículo científico publicado en 2012

Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.

artículo científico publicado en 2015

Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma

artículo científico publicado en 2013

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression

artículo científico publicado en 2007

Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study.

artículo científico publicado en 2010

Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathy

artículo científico publicado en 2015

Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma.

artículo científico publicado en 2010

The diagnostic performance of cardiac magnetic resonance in detection of myocardial involvement in AL amyloidosis

scientific article published on 13 November 2014

Unusual manifestation of AL amyloidosis--stenosis of inferior vena cava.

artículo científico publicado en 2006

Whole-body low-dose computed tomography in multiple myeloma staging: Superior diagnostic performance in the detection of bone lesions, vertebral compression fractures, rib fractures and extraskeletal findings compared to radiography with similar rad

artículo científico publicado en 2017

Lista de obras de Ivan Spicka

A dose exploration, phase I/II study of administration of continuous erythropoietin receptor activator once every 3 weeks in anemic patients with multiple myeloma receiving chemotherapy

A first Czech analysis of 1887 cases with monoclonal gammopathy of undetermined significance

A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma.

Adjusted comparison of daratumumab monotherapy versus real-world historical control data from the Czech Republic in heavily pretreated and highly refractory multiple myeloma patients.

Advances in multiple myeloma therapy during two past decades

An overview of the VISTA trial: newly diagnosed, untreated patients with multiple myeloma ineligible for stem cell transplantation

Asymptomatic and Treatment-requiring Multiple Myeloma - Data from the Czech Registry of Monoclonal Gammopathies

Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up.

Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.

Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study

Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment

Change in ploidy status from hyperdiploid to near-tetraploid in multiple myeloma associated with bortezomib/lenalidomide resistance

Characterization of a new human plasma cell leukemia cell line UHKT-944.

Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

Continuous prednisolone versus conventional prednisolone with VMCP-interferon-alpha2b as first-line chemotherapy in elderly patients with multiple myeloma.

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

Distinguishing of primary mediastinal B-cell lymphoma and diffuse large B-cell lymphoma using real-time quantitative polymerase chain reaction

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth

Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma

Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma.

Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy.

Health-Related Quality of Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.

Histone deacetylase inhibitors in plasma cell leukemia treatment: effect of bone marrow microenvironment.

IgM myeloma: A multicenter retrospective study of 134 patients

Immunotactoid glomerulonephritis as a cause of acute renal failure

Multicentered patient-based evidence of the role of free light chain ratio normalization in multiple myeloma disease relapse.

Novel human multiple myeloma cell line UHKT-893 ⬇️

Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production

Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.

Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.

Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression

Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study.

Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathy

Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma.

The diagnostic performance of cardiac magnetic resonance in detection of myocardial involvement in AL amyloidosis

Unusual manifestation of AL amyloidosis--stenosis of inferior vena cava.

Whole-body low-dose computed tomography in multiple myeloma staging: Superior diagnostic performance in the detection of bone lesions, vertebral compression fractures, rib fractures and extraskeletal findings compared to radiography with similar rad